Stromal Cell Therapy to get Recognized as Emerging anthracycline-Induced Cardiomyopathy Treatment

Release Date: 19-Nov-2020

Patients suffering from anthracycline-induced cardiomyopathy are estimated to receive benefits from transendocardial administration of allogenic bone marrow-derived mesenchymal stromal cells. As per the clinical research activity with 31 cancer survivors with chronic anthracycline-induced cardiomyopathy, patients receiving transendocardial administration of allogenic bone marrow-derived mesenchymal stromal cells were observed to be having better quality of life as well as an inclining trend towards walking a distance of 6 min when compared with the placebo group. In the clinical research study, 97% of the patients received successful injections and all the enrolled patients received the therapy at the desired dose.

It was also observed that 6 minute walking of the enrolled patients increased after one year when compared with the placebo group. Also, the Minnesota Living with Heart Failure Questionnaire score declined from 46.6 at baseline to 21.2 in the group that received the dose when compared with placebo group where score decline from only 53.1 to 40.5. It was concluded by the researchers based on the clinical trial, that the study was safe and feasible in the patients suffering from anthracycline-induced cardiomyopathy. The future clinical trial for the same study will make the researchers provide more useful data with respect to the study.